Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016
| Autor: | Kim M Hirshfield, Lingfeng Yang, Min Huang, Jan Sieluk, Amin Haiderali |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Triple Negative Breast Neoplasms Medicare 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Epidemiology medicine Humans 030212 general & internal medicine Stage (cooking) Triple-negative breast cancer Mastectomy Aged Retrospective Studies Aged 80 and over business.industry Retrospective cohort study General Medicine medicine.disease Combined Modality Therapy Progression-Free Survival United States Survival Rate 030220 oncology & carcinogenesis Costs and Cost Analysis Resource use Observational study Female business Adjuvant SEER Program |
| Zdroj: | Future oncology (London, England). 17(9) |
| ISSN: | 1744-8301 |
| Popis: | Aim: To examine real-world treatment patterns and outcomes in neoadjuvant and adjuvant settings for early-stage triple-negative breast cancer (TNBC). Patients & methods: Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients (≥65 years) with newly diagnosed stage II/III TNBC in 2010–2015 who had surgery plus neoadjuvant and/or adjuvant (systemic and/or radiation) therapy. Treatment, survival, healthcare resource use and costs were assessed through 2016. Results: Of 1569 patients (>99% women), 6%/74%/20% received neoadjuvant-only/adjuvant-only/both (neo + adj) therapies, respectively. Median overall survival was 23 months/not reached (NR)/78 months, with longer survival at stage II (NR/NR/78 months) than stage III (22/43/38 months). Mean per patient per month costs were $10,620 and $17,872 in neoadjuvant and adjuvant periods. Conclusion: These findings provide insights into clinical and economic outcomes for early-stage TNBC in 2010–2016. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|